一种新的药物性颌骨坏死临床分期及治疗策略

doi:10.19438/j.cjoms.2020.06.006

中国口腔颌面外科杂志 ›› 2020, Vol. 18 ›› Issue (6): 501-507.doi: 10.19438/j.cjoms.2020.06.006

一种新的药物性颌骨坏死临床分期及治疗策略

刘忠龙, 姜钧健, 李晓光, 祝奉硕, 唐晓, 朱凌, 何悦

上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面-头颈肿瘤科,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海市口腔医学研究所,上海 200011

收稿日期:2020-03-09 修回日期:2020-07-25 发布日期:2020-12-31
通讯作者: 何悦,E-mail:william5218@126.com
作者简介:刘忠龙(1988-),男,博士,E-mail:zhonglong021@126.com

A novel staging system and corresponding therapeutic strategies for medication-related osteonecrosis of the jaw

LIU Zhong-long, JIANG Jun-jian, LI Xiao-guang, ZHU Feng-shuo, TANG Xiao, ZHU Ling, HE Yue

Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology. Shanghai 200011, China

Received:2020-03-09 Revised:2020-07-25 Published:2020-12-31

摘要/Abstract

摘要： 目的: 通过分析药物性颌骨坏死(medication-related osteonecrosis of the jaw,MRONJ)的病例资料,提出一种用于指导MRONJ临床诊疗的新分期方法。方法: 总结2008—2018年上海交通大学医学院附属第九人民医院收治的74例MRONJ患者的影像学资料及诊疗方式,将下牙槽神经管、下颌骨下缘及上颌窦底等作为划分骨质破坏严重程度的解剖学标志,再根据病损组织是否存在明确的界线,提出了一种新的MRONJ四分期二亚分类法及相应的治疗策略。结果: 根据骨坏死的不同程度将其分为4期,0期(7例),Ⅰa期(18例),Ⅰb期(14例),Ⅱa期(12例),Ⅱb期(15例),Ⅲ期(8例)。治疗后62例患者病情稳定,12例出现骨坏死进展。结论: 新的分期方法及相应治疗策略适用于MRONJ的临床诊疗。

关键词: 药物性颌骨坏死, 临床分期, 治疗策略

Abstract: PURPOSE: To propose a new clinical staging method that can be performed to guide the diagnosis and treatment of MRONJ through a retrospective study of patients with medication-related osteonecrosis of the jaw (MRONJ). METHODS: The clinical data of 74 MRONJ patients admitted to Shanghai Ninth People's Hospital between 2008 and 2018 were enrolled. A novel staging method and corresponding treatments were proposed on the basis of anatomic structures (inferior alveolar canal and floor of maxillary sinus) and boundary of bone lesions. RESULTS: A new staging system with four different stages (stage 0: 7 cases; stageⅠa: 18 cases; stageⅠb: 14 cases; stage Ⅱa: 12 cases; stage Ⅱb: 15 cases; and stage Ⅲ: 8 cases) was proposed. Outcome of these samples demonstrated that only 12 cases hold progressed state. CONCLUSIONS: This new staging system is suitable for clinical diagnosis and therapeutic selection for MRONJ.

Key words: Medication-related osteonecrosis of the jaw, Clinical staging, Therapeutic strategy

中图分类号:

R739.8

刘忠龙, 姜钧健, 李晓光, 祝奉硕, 唐晓, 朱凌, 何悦. 一种新的药物性颌骨坏死临床分期及治疗策略[J]. 中国口腔颌面外科杂志, 2020, 18(6): 501-507.

LIU Zhong-long, JIANG Jun-jian, LI Xiao-guang, ZHU Feng-shuo, TANG Xiao, ZHU Ling, HE Yue. A novel staging system and corresponding therapeutic strategies for medication-related osteonecrosis of the jaw[J]. China J Oral Maxillofac Surg, 2020, 18(6): 501-507.

参考文献

[1] Marx RE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9):1115-1117.
[2] Diniz-Freitas M, Pena-Cristobal M, Pérez-López D, et al.Bibliometric analysis of medication-related osteonecrosis of the jaw: high citation rates but low evidence[J]. J Oral Maxillofac Surg, 2019, 77(8): 1655e1-1655 e17.
[3] Ruggiero SL, Dodson TB, Fantasia J, et al.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update[J]. J Oral Maxillofac Surg, 2014, 72(10): 1938-1956.
[4] Yamada SI, Kurita H, Kondo E, et al.Treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw: a case- and literature-based review[J]. Clin Oral Investig, 2019, 23(8): 3203-3211.
[5] Favia G, Tempesta A, Limongelli L, et al.Medication-related osteonecrosis of the jaw: Surgical or non-surgical treatment?[J] Oral Dis, 2018, 24(1-2): 238-242.
[6] Hayashida S, Soutome S, Yanamoto S, et al.Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: a multicenter retrospective study with propensity score matching analysis[J]. J Bone Miner Res, 2017, 32(10): 2022-2029.
[7] Eguchi T, Kanai I, Basugi A, et al.The assessment of surgical and non-surgical treatment of stage II medication-related osteonecrosis of the jaw[J]. Med Oral Patol Oral Cir Bucal, 2017, 22(6): e788-e795.
[8] Hermans R, Fossion E, Ioannides C, et al.CT findings in osteoradionecrosis of the mandible[J]. Skeletal Radiology,1996, 25(1):31-36.
[9] Store G, Larheim TA.Mandibular osteoradionecrosis: a comparison of computed tomography with panoramic radiography[J]. Dentomaxillofac Radiol, 1999, 28(5): 295-300.
[10] Mücke T, Krestan CR, Mitchell DA, et al.Bisphosphonate and medication-related osteonecrosis of the jaw: a review[J]. Semin Musculoskelet Radiol, 2016, 20(3): 305-314.
[11] Ristow O, Otto S, Troeltzsch M, et al.Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ)[J]. J Craniomaxillofac Surg, 2015, 43(2): 290-293.
[12] Aljohani S, Troeltzsch M, Hafner S, et al.Surgical treatment of medication- related osteonecrosis of the upper jaw: Case series[J]. Oral Dis, 2019, 25(2): 497-507.
[13] Baba A, Goto TK, Ojiri H, et al.CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw[J]. Dentomaxillofac Radiol, 2018, 47(4): 20170323.
[14] Marx RE.Reconstruction of defects caused by bisphosphonate-induced osteonecrosis of the jaws[J]. J Oral Maxillofac Surg, 2009,67(5 Suppl): 107-119.
[15] Mücke T, Jung M, Koerdt S, et al.Free flap reconstruction for patients with bisphosphonate related osteonecrosis of the jaws after mandibulectomy[J]. J Craniomaxillofac Surg, 2016, 44(2): 142-147.
[16] Pautke C, Otto S, Reu S, et al.Bisphosphonate related osteonecrosis of the jaw-manifestation in a microvascular iliac bone flap[J]. Oral Oncol, 2011, 47(5): 425-429.
[17] Vercruysse H Jr, Backer Td, Mommaerts MY.Outcomes of osseous free flap reconstruction in stage III bisphosphonate-related osteonecrosis of the jaw: systematic review and a new case series[J]. J Craniomaxillofac Surg, 2014, 42(5): 377-386.
[18] El-Rabbany M, Sgro A, Lam DK, et al.Effectiveness of treatments for medication-related osteonecrosis of the jaw: A systematic review and meta-analysis[J]. J Am Dent Assoc, 2017, 148(8): 584-594.
[19] Caldroney S, Ghazali N, Dyalram D, et al.Surgical resection and vascularized bone reconstruction in advanced stage medication-related osteonecrosis of the jaw[J]. Int J Oral Maxillofac Surg, 2017, 46(7): 871-876.
[20] El-Rabbany M, Lam DK, Shah PS, et al.Surgical management of medication-related osteonecrosis of the jaw is associated with improved disease resolution: a retrospective cohort study[J]. J Oral Maxillofac Surg, 2019, 77(9):1816-1822.

一种新的药物性颌骨坏死临床分期及治疗策略

A novel staging system and corresponding therapeutic strategies for medication-related osteonecrosis of the jaw

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价

[1]	吴亚平, 高嘉敏, 孙树洋. HPV相关口咽癌诊疗进展[J]. 中国口腔颌面外科杂志, 2022, 20(6): 599-606.
[2]	胡龙威, 颜然, 文晋, 张陈平, 赵小妹, 李思毅. 127例药物性颌骨坏死患者回顾性分析：单中心10年经验总结[J]. 中国口腔颌面外科杂志, 2022, 20(1): 72-76.
[3]	郑家伟. 婴幼儿血管瘤“等待观察”的治疗策略应予改变 [J]. 中国口腔颌面外科杂志, 2012, 10(2): 163-164.